

AMENDMENTS

In the specification:

Please amend paragraph [0186] on page 56 of the specification as follows:

[0186] In a preferred embodiment, the immunomodulatory agent decreases the amount of IL-9. In a more preferred embodiment, the immunomodulatory agent is an antibody (preferably a monoclonal antibody) or fragment thereof that immunospecifically binds to IL-9 (see e.g., U.S. Patent Application No. [[]10/823,810 filed April 12, 2004 entitled “Methods of Preventing or Treating Respiratory Conditions” by Reed (Attorney Docket No. 10271-113-999), U.S. Patent Application No. [[]10/823,253 filed April 12, 2004 entitled “Recombinant IL-9 Antibodies and Uses Thereof” by Reed (Attorney Docket No. 10271-112-999), and U.S. Patent Application No. [[]11/105,268 filed April 12, 2004 entitled “Anti-IL-9 Antibody Formulations and Uses Thereof” by Reed (Attorney Docket No. 10271-126-999), all of which are incorporated by reference herein in their entireties. Although not intending to be bound by a particular mechanism of action, the use of anti-IL-9 antibodies neutralizes IL-9’s biological effect and, thereby, blocks or decreases inflammatory cell recruitment, epithelial or neointimal hyperplasia, and mucin production of epithelial cells.